The 27 Wall Street analysts covering Medline, Inc. hold a median 12-month price target of $45 — +11.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 32 of 100 as at 4 Nov 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.
Consensus tells you what everyone already believes. The model scores Medline, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Revisions (85): Analysts have, on balance, been raising their forecasts.
Volatility (1): The share price moves around a lot.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on MDLN, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +11.4% from it.
Of the 20 most recent actions, 0 moved their price target up and 9 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 22 Oct 2026 | Mizuho | Maintains | Outperform | $48 → $45 |
| 9 Oct 2026 | Barclays | Maintains | Overweight | $45 → $43 |
| 9 Oct 2026 | Barclays | Maintains | Overweight | — |
| 25 Sept 2026 | UBS | Maintains | Buy | — |
| 25 Sept 2026 | UBS | Maintains | Buy | $45 → $43 |
| 27 Aug 2026 | BTIG | Reiterates | Buy | $55 |
| 27 Aug 2026 | BTIG | Reiterates | Buy | — |
| 12 Aug 2026 | JP Morgan | Maintains | Overweight | — |
| 12 Aug 2026 | JP Morgan | Maintains | Overweight | $53 → $46 |
| 11 Aug 2026 | Tigress Financial | Maintains | Buy | $62 → $55 |
| 11 Aug 2026 | Tigress Financial | Maintains | Buy | — |
| 11 Aug 2026 | Wells Fargo | Maintains | Equal-Weight | — |
| 11 Aug 2026 | Wells Fargo | Maintains | Equal-Weight | $45 → $34 |
| 10 Aug 2026 | TD Cowen | Maintains | Buy | $53 → $45 |
| 10 Aug 2026 | TD Cowen | Maintains | Buy | — |
| 6 Aug 2026 | Evercore ISI Group | Maintains | Outperform | — |
| 6 Aug 2026 | Evercore ISI Group | Maintains | Outperform | $48 → $39 |
| 6 Aug 2026 | RBC Capital | Maintains | Outperform | — |
| 6 Aug 2026 | RBC Capital | Maintains | Outperform | $53 → $46 |
| 6 Aug 2026 | Stifel | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
MDLN appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 9% of US stocks
Cheaper than 58% of US stocks
Cheaper than 35% of US stocks
Cheaper than 16% of US stocks
Higher than 57% of US stocks
Higher than 5% of US stocks
Higher than 32% of US stocks
Higher than 46% of US stocks
Higher than 53% of US stocks
Higher than 53% of US stocks
Higher than 62% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Medline, Inc. has a market value of $45.2B and an enterprise value of $47.0B.
Diluted earnings per share, trailing twelve months: $0.40.
Trailing P/E: 80.1×; forward P/E: 21.4× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Medline, Inc. employs 45,000 people.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Medline, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Medline reported third-quarter revenue growth of 10% year over year to $7.9 billion and adjusted EBITDA growth of 12% to $1 billion. The company raised its full-year organic sales growth outlook for a third consecutive quarter.
Why it matters — The results and outlook update provide MDLN watchers with information about quarterly growth across Medline’s businesses and the company’s sales outlook.
Zacks Investment Research notes that Medline’s Q3 top- and bottom-line results cover the quarter ended September 2026. The excerpt says key metrics can also be compared with Wall Street estimates and year-ago values but provides no metric results.
Why it matters — MDLN watchers may want to consider these comparisons alongside the headline earnings figures when assessing quarterly performance.
Medline reported operating results for the three and nine months ended September 26, 2026.
Why it matters — The report provides MDLN watchers with the company's latest quarterly and year-to-date operating results.
Bleichmar Fonti & Auld LLP announced an investigation into Medline Inc. over potential securities fraud following significant stock drops. The firm directed investors to its website for additional information.
Why it matters — The investigation concerns Medline securities and follows reported stock drops, making it relevant to MDLN watchers.
Medline announced that CEO Jim Boyle is scheduled to present at the Jefferies Global Healthcare Conference in London on November 17, 2026, at 3:30 p.m. GMT.
Why it matters — MDLN watchers may note the scheduled conference appearance as an opportunity for the company’s CEO to address investors and other attendees.
The 27 Wall Street analysts covering Medline, Inc. have a median 12-month price target of $45, with estimates ranging from $34 to $55. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 27 analysts covering Medline, Inc., 23 rate it a Buy, 4 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Medline, Inc. 32 out of 100 across roughly 4,600 US stocks as at 4 Nov 2026. None of this is personal advice — it does not consider your circumstances.
As at 4 Nov 2026, Medline, Inc. ranks 32 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Revisions (85 of 100).
No one can know that. What the data says: the median 12-month target from 27 analysts implies +11.4% from the last close, and Ticker Nerd's factor model ranks Medline, Inc. 32 out of 100 as at 4 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Medline, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for MDLN are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $34 to $55 over the next 12 months.
Medline Inc. Class A Common Stock represents ownership in Medline Inc., a healthcare company focused on medical-surgical products and supply chain solutions.
The most recent item we track (MarketBeat, 4 Nov 2026): "Medline Q3 Earnings Call Highlights". Medline reported third-quarter revenue growth of 10% year over year to $7.9 billion and adjusted EBITDA growth of 12% to $1 billion. The company raised its full-year organic sales growth outlook for a third consecutive quarter.
Medline Inc. Class A Common Stock represents ownership in Medline Inc., a healthcare company focused on medical-surgical products and supply chain solutions. Medline serves hospitals, ambulatory surgery centers, physician offices, post-acute facilities, and nursing homes through a broad portfolio of products and services used across everyday clinical care. Its business is organized around product manufacturing and procurement, as well as logistics and distribution support for healthcare customers. The company also provides tailored supply chain solutions designed to help healthcare providers manage sourcing, inventory, and delivery across multiple care settings. Medline’s role in the market is centered on supporting the operational needs of the healthcare industry with essential supplies and integrated services.
CEO Mr. James M. Boyle · 45,000 employees · United States · https://www.medline.com
